Clinical trial
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for…
NCT00215566 · Dynogen Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00215566 |
|---|---|
| Title | A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c |
| Official title | A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Doses and Dose Levels of DDP733 in Patients With Irritable Bowel Syndrome With Constipation |
| Lead sponsor | Dynogen Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome |
| Intervention type | Drug |
| Interventions | DDP733 |
| Enrollment | 90 |
| Start date | Sep 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | May 28, 2007 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: